In the CIGMA trial, the use of trimodulin (a human polyvalent immunoglobulin preparation) was associated with more rapid normalization of inflammatory markers and lower mortality in sCAP patients with low lymphocyte or IgM levels (42). This evidence concerns the gene CD40LG and syringocystadenoma papilliferum.